Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1994 Apr 1;150(7):1083–1090.

Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.

B J O'Brien 1, D R Anderson 1, R Goeree 1
PMCID: PMC1486381  PMID: 8137188

Abstract

OBJECTIVE: To compare the efficacy and cost-effectiveness of enoxaparin, a low-molecular-weight heparin derivative, with that of low-dose warfarin in the prevention of deep-vein thrombosis (DVT) after total hip replacement. DATA SOURCES: English-language articles on enoxaparin and warfarin prophylaxis is patients undergoing total hip replacement published from January 1982 to December 1992. STUDY SELECTION: Four trials of enoxaparin (involving 567 patients) and six trials of warfarin (involving 630) met the following criteria: randomized controlled trial, prophylaxis started no later than 24 hours after surgery and continued for at least 7 days, warfarin dose monitored and adjusted appropriately, enoxaparin dosage 30 mg twice daily, and DVT confirmed by bilateral venography. DATA EXTRACTION: Rates of DVT, cost of prophylaxis, diagnosis and treatment per patient, rate of pulmonary embolism (PE), number of deaths and incremental cost-effectiveness (cost per life-year gained). DATA SYNTHESIS: The pooled rate of DVT was 13.6% with enoxaparin (95% confidence interval [CI] 10.9% to 16.3%) and 20.6% with warfarin (95% CI 17.4% to 23.8%). At a cost of $19.55 per day for enoxaparin the total cost per patient, including prophylaxis and management of DVT, exceeded that per patient receiving warfarin by about $121. For every 10,000 patients treated the use of enoxaparin will prevent 47 cases of DVT, 3 cases of PE and 4 deaths. Thus, the estimated incremental cost-effectiveness of enoxaparin is $29 120 per life-year gained. CONCLUSION: On the basis of current Canadian cost-effectiveness guidelines the results of this study would be considered moderate to strong evidence to adopt enoxaparin prophylaxis against DVT after total hip replacement. However, because of the limited data the estimates are uncertain. Future trials should compare enoxaparin and warfarin and incorporate a prospective economic appraisal.

Full text

PDF
1084

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bailey J. P., Kruger M. P., Solano F. X., Zajko A. B., Rubash H. E. Prospective randomized trial of sequential compression devices vs low-dose warfarin for deep venous thrombosis prophylaxis in total hip arthroplasty. J Arthroplasty. 1991;6 (Suppl):S29–S35. doi: 10.1016/s0883-5403(08)80053-8. [DOI] [PubMed] [Google Scholar]
  2. Carson J. L., Kelley M. A., Duff A., Weg J. G., Fulkerson W. J., Palevsky H. I., Schwartz J. S., Thompson B. T., Popovich J., Jr, Hobbins T. E. The clinical course of pulmonary embolism. N Engl J Med. 1992 May 7;326(19):1240–1245. doi: 10.1056/NEJM199205073261902. [DOI] [PubMed] [Google Scholar]
  3. Dalen J. E., Alpert J. S. Natural history of pulmonary embolism. Prog Cardiovasc Dis. 1975 Jan-Feb;17(4):259–270. doi: 10.1016/s0033-0620(75)80017-x. [DOI] [PubMed] [Google Scholar]
  4. Detsky A. S. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. Pharmacoeconomics. 1993 May;3(5):354–361. doi: 10.2165/00019053-199303050-00003. [DOI] [PubMed] [Google Scholar]
  5. Doubilet P., Weinstein M. C., McNeil B. J. Use and misuse of the term "cost effective" in medicine. N Engl J Med. 1986 Jan 23;314(4):253–256. doi: 10.1056/NEJM198601233140421. [DOI] [PubMed] [Google Scholar]
  6. Egermayer P. Value of anticoagulants in the treatment of pulmonary embolism: a discussion paper. J R Soc Med. 1981 Sep;74(9):675–681. doi: 10.1177/014107688107400911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Francis C. W., Marder V. J., Evarts C. M., Yaukoolbodi S. Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding. JAMA. 1983 Jan 21;249(3):374–378. doi: 10.1001/jama.249.3.374. [DOI] [PubMed] [Google Scholar]
  8. Francis C. W., Pellegrini V. D., Jr, Marder V. J., Totterman S., Harris C. M., Gabriel K. R., Azodo M. V., Leibert K. M. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA. 1992 Jun 3;267(21):2911–2915. [PubMed] [Google Scholar]
  9. Gallus A., Jackaman J., Tillett J., Mills W., Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet. 1986 Dec 6;2(8519):1293–1296. doi: 10.1016/s0140-6736(86)91431-5. [DOI] [PubMed] [Google Scholar]
  10. Heijboer H., Cogo A., Büller H. R., Prandoni P., ten Cate J. W. Detection of deep vein thrombosis with impedance plethysmography and real-time compression ultrasonography in hospitalized patients. Arch Intern Med. 1992 Sep;152(9):1901–1903. [PubMed] [Google Scholar]
  11. Hirsh J., Levine M. N. Low molecular weight heparin. Blood. 1992 Jan 1;79(1):1–17. [PubMed] [Google Scholar]
  12. Hull R. D., Raskob G. E., Pineo G. F., Green D., Trowbridge A. A., Elliott C. G., Lerner R. G., Hall J., Sparling T., Brettell H. R. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992 Apr 9;326(15):975–982. doi: 10.1056/NEJM199204093261502. [DOI] [PubMed] [Google Scholar]
  13. Hull R. D., Raskob G. E., Rosenbloom D., Panju A. A., Brill-Edwards P., Ginsberg J. S., Hirsh J., Martin G. J., Green D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990 May 3;322(18):1260–1264. doi: 10.1056/NEJM199005033221802. [DOI] [PubMed] [Google Scholar]
  14. Kaempffe F. A., Lifeso R. M., Meinking C. Intermittent pneumatic compression versus coumadin. Prevention of deep vein thrombosis in lower-extremity total joint arthroplasty. Clin Orthop Relat Res. 1991 Aug;(269):89–97. [PubMed] [Google Scholar]
  15. Kakkar V. V., Howe C. T., Flanc C., Clarke M. B. Natural history of postoperative deep-vein thrombosis. Lancet. 1969 Aug 2;2(7614):230–232. doi: 10.1016/s0140-6736(69)90002-6. [DOI] [PubMed] [Google Scholar]
  16. Laird N. M., Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care. 1990;6(1):5–30. doi: 10.1017/s0266462300008916. [DOI] [PubMed] [Google Scholar]
  17. Laupacis A., Feeny D., Detsky A. S., Tugwell P. X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992 Feb 15;146(4):473–481. [PMC free article] [PubMed] [Google Scholar]
  18. Levine M. N., Hirsh J., Gent M., Turpie A. G., Leclerc J., Powers P. J., Jay R. M., Neemeh J. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med. 1991 Apr 1;114(7):545–551. doi: 10.7326/0003-4819-114-7-545. [DOI] [PubMed] [Google Scholar]
  19. Oster G., Tuden R. L., Colditz G. A. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA. 1987 Jan 9;257(2):203–208. [PubMed] [Google Scholar]
  20. Paiement G. D., Wessinger S. J., Harris W. H. Survey of prophylaxis against venous thromboembolism in adults undergoing hip surgery. Clin Orthop Relat Res. 1987 Oct;(223):188–193. [PubMed] [Google Scholar]
  21. Paiement G., Wessinger S. J., Waltman A. C., Harris W. H. Low-dose warfarin versus external pneumatic compression for prophylaxis against venous thromboembolism following total hip replacement. J Arthroplasty. 1987;2(1):23–26. doi: 10.1016/s0883-5403(87)80027-x. [DOI] [PubMed] [Google Scholar]
  22. Pedersen O. M., Aslaksen A., Vik-Mo H., Bassoe A. M. Compression ultrasonography in hospitalized patients with suspected deep venous thrombosis. Arch Intern Med. 1991 Nov;151(11):2217–2220. [PubMed] [Google Scholar]
  23. Prandoni P., Lensing A. W., Büller H. R., Carta M., Cogo A., Vigo M., Casara D., Ruol A., ten Cate J. W. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992 Feb 22;339(8791):441–445. doi: 10.1016/0140-6736(92)91054-c. [DOI] [PubMed] [Google Scholar]
  24. Thompson S. G., Pocock S. J. Can meta-analyses be trusted? Lancet. 1991 Nov 2;338(8775):1127–1130. doi: 10.1016/0140-6736(91)91975-z. [DOI] [PubMed] [Google Scholar]
  25. Turpie A. G., Levine M. N., Hirsh J., Carter C. J., Jay R. M., Powers P. J., Andrew M., Hull R. D., Gent M. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med. 1986 Oct 9;315(15):925–929. doi: 10.1056/NEJM198610093151503. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES